Lungcast American Lung Association & HCPLive

0:16 Intro
2:29 Updated community-acquired pneumonia guidelines
5:41 Diagnostic tools for CAP following COVID-19
9:35 Procalcitonin levels as a biomarker
12:30 The CAP treatment algorithm
18:36 Best practices for antibiotic stewardship
20:40 New CAP therapies on the horizon
22:36 ACIP recommendations for vaccination
24:30 Remaining areas of CAP uncertainty
26:30 Final thoughts
27:25 Outro

Featuring infectious disease expert Dr. Thomas File of Summa Health in Ohio, this episode delves into how community-acquired pneumonia has been affected by the COVID-19 pandemic. It additionally covers the role and importance of antibiotic stewardship and the concern of ‘superbugs’ due to antimicrobial resistance.

Want more Lungcast? Visit us at HCPLive.com/podcasts/lungcast or www.lung.org/professional-education/lungcast

Episode Highlights

0:11 Intro
1:05 Introducing Stephanie Lovinsky-Desir, MD, MS
2:09 Understanding asthma endotypes and phenotypes
5:03 The effect of SMART guideline updates
11:50 Are pulmonary & allergy specialists adopting it?
12:46 The value of biologics in asthma care
18:11 Could they interrupt the atopic march?
19:53 COVID-19 risks in asthma
23:24 Environmental and non-viral illness impacts on asthma
26:11 Research into asthma care inequities
31:47 HFA-containing metered dose inhalers
35:37 Outro

In honor of World Asthma Day, Dr. Stephanie Lovinsky-Desir of Columbia University Irving Medical Center in New York visits our virtual studio to talk about all things asthma. Dr. Lovinsky-Desir, who has a deep understanding of how environmental factors impact children with asthma, touches upon inequities in asthma care, the role of climate change and COVID-19 lessons learned. She also hones in on whether biologic therapies may help interrupt pathways in the atopic march.

Want more Lungcast? Visit us at HCPLive.com/podcasts/lungcast or www.lung.org/professional-education/lungcast

Episode Highlights
0:16 Intro
2:17 What caused the particle pollution spike?
6:28 The health effects of fine particle pollution exposure
10:23 The new EPA particle pollution standard
14:27 Improvements to ozone pollution and the Clean Air Act
18:46 How to advocate for improvement
20:23 Air quality inequity
24:03 Reflecting on 25 years, and looking ahead
25:52 Outro 

Dr. John Balmes, a renowned environmental health sciences expert from the University of California, San Francisco, join Lungcast for a deep dive into the American Lung Association’s newly released 2024 “State of the Air” report. Balmes specifically provides context behind several concerning trends, notably a spike in deadly particle pollution—the highest levels in the past 25 years largely due to wildfires. 

The eye-opening conversation also impresses upon the importance of clean transportation and power generation to help mitigate population-wide risk. 

Want more Lungcast? Visit us at HCPLive.com/podcasts/lungcast or www.lung.org/professional-education/lungcast

0:16 Intro
2:28 Recent modifications to the lung allocation score
5:11 Monitoring chronic graft rejection
9:23 The rising use of ex vivo lung perfusion 
16:17 The presence of post-COVID patients on the lung transplant waitlist
21:01 Impact of long Covid on transplant rehabilitation
22:51 Double lung transplant in bilateral lung cancer—what’s the future?
26:52 Effect of LAS on lung transplant survival racial disparity
31:05 What lies ahead in the practice of lung transplantation
35:00 Outro

Cleveland Clinic’s Maryam Valapour, MD, MPP, rejoins the broadcast, along with her colleague Kenneth McCurry, MD to discuss optimization of the lung allocation system to continue reducing waitlist times and patient mortality. 

It includes commentary on how recent changes to scoring protocols are expected to impact ongoing disparities related to race and socioeconomic status. They additionally talk about the role of transplantation in patients who have severely damaged lungs resulting from COVID-19 infection, an update since our April 2021 conversation.

Want more Lungcast? Visit us at HCPLive.com/podcasts/lungcast or www.lung.org/professional-education/lungcast

Episode Highlights
0:15 Intro
3:09 Low-dose CT screening uptake in Canada
4:45 Evolution of adjuvant, neoadjuvant therapies
7:10 Reviewing CheckMate 816
10:56 Reviewing KEYNOTE-671
12:58 The impact of neoadjuvants on operability
16:15 Treatment-specific biomarkers for lung cancer
21:13 The short-term future of lung cancer therapy
24:31 Outro

Precision medicine–delivering the right drug at the right time to the right patient–is the direction in which lung cancer treatment is heading. In this episode, we talk about an exciting, emerging drug class with one of the most prominent investigators involved with its development, Dr. Jonathan Spicer at McGill University’s Thoracic Oncology Network. 

It provides a deep dive into neoadjuvant therapy for patients who have operable lung cancer, offering insight into what is currently known about response and failure rates.

Want more Lungcast? Visit us at HCPLive.com/podcasts/lungcast or www.lung.org/professional-education/lungcast

Episode Highlights

0:15 Intro
1:48 Remembering the 1964 Surgeon General Report
3:01 The impact of the report on cardiology
6:47 The strategies and impact of anti-smoking campaigns
10:33 The modern vaping challenge
17:38 Outro

In recognition of 60 years since the 1964 Surgeon General Report—a historic contribution to our understanding of the negative health impacts of cigarette smoking—host Albert Rizzo, MD, meets with preventive cardiology expert Viet Le, DMSc, PA-C to reflect on the myriad of cascading effects delivered by this landmark report.

Want more Lungcast? Visit us at HCPLive.com/podcasts/lungcast or www.lung.org/professional-education/lungcast